Article
Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.
BMC cancer - 10 Oct 2025
Pinar Ibrahim Ethem, Celik Serhat, Polat Merve Gokcen, Karatas Aylin Fatma, Dogan Ali, Iltar Utku, Cengiz Seval Guldane, Malkan Umit Yavuz, Ince Idris, Yenihayat Emel Merve, Akdeniz Aydan, Kacmaz Murat, Erdem Ramazan, Afacan Ozturk Hacer Berna, Kirkizlar Hakki Onur, Korkmaz Gulten, Aykas Fatma, Mehtap Ozgur, Deveci Burak, Sevindik Omur Gokmen, Can Ferda, Ozbalci Demircan, Bulbul Hale, Durusoy Salih Sertac, Atas Unal, Keklik Muzaffer, Toprak Selami Kocak, Goker Hakan, Demirkan Fatih, Ozkalemkas Fahir, Alacacioglu Inci, Karakus Volkan
Abstract excerpt
BACKGROUND: This study aimed to evaluate the prognostic significance and clinical impact of the revised 2022 European LeukemiaNet (ELN) classification for acute myeloid leukemia (AML), focusing particularly on patients harboring fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations. METHODS: A retrospective, multicenter observational study was conducted by the Turkish Society of...
Read the complete abstract on PubMedTopics
- Adolescent
- Adult
- Aged